Prof William Pao to head Roche oncology unit
This article was originally published in Scrip
Executive Summary
Swiss pharma Roche has named professor of medicine at Vanderbilt University Medical Center, William Pao, global head of its oncology disease and translational unit – effective 1 May 2014. He will be based in Basel, Switzerland and will report to Dr John Reed global head of Roche Pharma Research and Early Development (pRED). Professor Pao is currently an advisor to the National Cancer Institute (NCI), American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), and other professional societies, while also serving on the editorial boards of several medical research journals including Cancer Research, Clinical Cancer Research, and Journal of Clinical Oncology. Furthermore, Professor Pao is a co-founder of MyCancerGenome, a web-based tool for clinical decision support to enable a genetically informed approach to cancer medicine. At Roche he will be responsible for leading the company's discovery, translational medicine and early development of innovative oncology medicines.